Cargando…
Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies
Acute myeloid leukemia (AML) arising from myeloproliferative neoplasms (MPNs) represents a small subtype of secondary AML (sAML). This entity is well known to be associated with poor responses to available treatment options and dismal outcomes. To date, there are no standardized treatment options an...
Autores principales: | McKinnell, Zoe, Karel, Daniel, Tuerff, Daniel, SH Abrahim, Marwa, Nassereddine, Samah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822656/ https://www.ncbi.nlm.nih.gov/pubmed/36632576 http://dx.doi.org/10.14740/jh1042 |
Ejemplares similares
-
Thymic neuroendocrine neoplasms—what we know, what we don’t know, and what to do about it
por: Lang, Matthias, et al.
Publicado: (2023) -
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know
por: Dhawan, Rahul, et al.
Publicado: (2020) -
The origin of life: what we know, what we can know and what we will never know
por: Pross, Addy, et al.
Publicado: (2013) -
Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018) -
International Trade and Investment and Food Systems: What We Know, What We Don’t Know, and What We Don’t Know We Don’t Know
por: Schram, Ashley, et al.
Publicado: (2020)